Skip to main content
. 2020 Sep 2;41(2):381–390. doi: 10.1007/s00296-020-04667-5

Fig. 1.

Fig. 1

Patient identification. bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; ETN, etanercept; LDA, low disease activity; RA, rheumatoid arthritis; TNFi, tumor necrosis factor inhibitor